MX358055B - Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares. - Google Patents
Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares.Info
- Publication number
- MX358055B MX358055B MX2014008295A MX2014008295A MX358055B MX 358055 B MX358055 B MX 358055B MX 2014008295 A MX2014008295 A MX 2014008295A MX 2014008295 A MX2014008295 A MX 2014008295A MX 358055 B MX358055 B MX 358055B
- Authority
- MX
- Mexico
- Prior art keywords
- reovirus
- immune
- proliferative disorders
- mammal
- treatment
- Prior art date
Links
- 241000702263 Reovirus sp. Species 0.000 title abstract 7
- 230000002062 proliferating effect Effects 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 230000001413 cellular effect Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000987 immune system Anatomy 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 230000009089 cytolysis Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000283707 Capra Species 0.000 abstract 1
- 241000283086 Equidae Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000702244 Orthoreovirus Species 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000003292 diminished effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000012385 systemic delivery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
Abstract
La presente invención se refiere a métodos para evitar el reconocimiento de reovirus en el tratamiento de trastornos proliferantes celulares, y particularmente a trastornos proliferantes celulares mediados por ras, en mamíferos. El mamífero puede seleccionarse de perros, gatos, borregos, cabras, ganado, caballos, cerdos, ratones, humanos y primates no humanos. El método comprende suprimir o de otra manera inhibir el sistema inmune del mamífero y, en forma concurrente o subsecuente, administrar a las células proliferantes una cantidad efectiva de uno o más reovirus bajo condiciones que resulten en la lisis sustancial de las células proliferantes. En particular, los métodos proporcionan el tratamiento con reovirus de mamíferos inmunosuprimidos o inmunodeficientes para tratar los trastornos proliferantes. La inmunosupresión, inmunoinhibición o de otra manera inducción de un estado inmunodeficiente en un mamífero hace al reovirus más efectivo. Los métodos pueden incluir la remoción selectiva de constituyentes inmunes que pudieran interferir con el suministro sistémico del virus; evitar el reconocimiento del reovirus por el sistema inmune del hospedero y la remoción del virus de un hospedero inmunoincompetente o inmunosuprimido después del tratamiento con el reovirus. Como alternativa, el reovirus se puede administrar a un mamífero con un sistema de respuesta inmune disminuido bajo condiciones que den como resultado la lisis sustancial de las células proliferantes. Los sistemas inmunes pueden ser comprometidos mediante uno o más de los siguientes: una infección por VIH; como un efecto secundario de quimioterapia o terapia con radiación; mediante la remoción selectiva de poblaciones de células B y/o T; mediante la remoción de anticuerpos (anticuerpos anti-antirreovirus o todos los anticuerpos), y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/636,597 US6565831B1 (en) | 1999-02-24 | 2000-08-10 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| PCT/CA2001/001055 WO2002011742A2 (en) | 2000-08-10 | 2001-07-20 | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX358055B true MX358055B (es) | 2018-08-03 |
Family
ID=24552555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008295A MX358055B (es) | 2000-08-10 | 2001-07-20 | Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares. |
| MXPA03000859A MXPA03000859A (es) | 2000-08-10 | 2001-07-20 | Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03000859A MXPA03000859A (es) | 2000-08-10 | 2001-07-20 | Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US6565831B1 (es) |
| EP (3) | EP2016948A3 (es) |
| JP (1) | JP2004505924A (es) |
| AR (1) | AR029839A1 (es) |
| AT (1) | ATE422358T1 (es) |
| AU (2) | AU2001276218B8 (es) |
| BR (1) | BR0113128A (es) |
| CA (1) | CA2415750C (es) |
| DE (1) | DE60137631D1 (es) |
| ES (1) | ES2317921T3 (es) |
| IL (2) | IL153846A0 (es) |
| MX (2) | MX358055B (es) |
| NZ (1) | NZ523509A (es) |
| WO (1) | WO2002011742A2 (es) |
| ZA (1) | ZA200300411B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| MXPA03004029A (es) * | 2000-11-09 | 2004-02-12 | Oncolytics Biotech Inc | Metodos para tratamiento de trastornos proliferativos celulares. |
| AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| AU2002335667A1 (en) * | 2001-08-03 | 2003-02-17 | Board Of Regents, The University Of Texas System | Modified reoviral therapy |
| US20040115170A1 (en) * | 2001-11-30 | 2004-06-17 | Brown Earl Garnet | Oncolytic virus |
| WO2003094939A1 (en) * | 2002-05-10 | 2003-11-20 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| CA2522711A1 (en) * | 2003-04-25 | 2004-11-11 | Wellstat Biologics Corporation | Treating hepatocellular carcinomas using therapeutic viruses |
| US20050019308A1 (en) * | 2003-07-07 | 2005-01-27 | Oncolytics Biotech Inc. | Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac |
| WO2005043155A1 (en) * | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| US20050137152A1 (en) * | 2003-12-19 | 2005-06-23 | Danny Cheung | Reovirus for the prevention of neoplasia |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| US20070065514A1 (en) * | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| LT1983984T (lt) | 2006-02-02 | 2018-06-11 | Novartis Ag | Tuberozinės sklerozės gydymas |
| AU2011205053B2 (en) * | 2006-02-02 | 2013-02-07 | Novartis Ag | Tuberous Sclerosis treatment |
| AU2007215328A1 (en) * | 2006-02-13 | 2007-08-23 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
| US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
| MX2009009598A (es) * | 2007-03-12 | 2009-09-21 | Oncolytics Biotech Inc | Reovirus que tienen secuencias modificadas. |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| AR066649A1 (es) * | 2007-05-21 | 2009-09-02 | Oncolytics Biotech Inc | Reovirus mutantes y metodos de elaboracion y uso de los mismos |
| JP2011500608A (ja) * | 2007-10-22 | 2011-01-06 | オンコリティクス バイオテク，インコーポレーテッド | 増殖性障害の治療レジメン |
| WO2009135614A2 (en) * | 2008-05-09 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | Use of a virus regimen for the treatment of diseases |
| TW200951143A (en) * | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
| US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| US9707285B2 (en) | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| WO2015103447A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| WO2012075379A2 (en) * | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
| RU2684211C2 (ru) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| CA2930629A1 (en) | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4108983A (en) | 1976-06-01 | 1978-08-22 | The Wistar Institute | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| AU5275290A (en) | 1989-04-11 | 1990-11-05 | Board Of Regents, The University Of Texas System | Antitumor preparation obtained following oncolysate treatment |
| CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| CA2051289C (en) | 1990-09-14 | 2002-11-26 | Robert L. Martuza | Viral mediated destruction of neoplastic cells |
| AU682854B2 (en) | 1993-02-16 | 1997-10-23 | Onyx Pharmaceuticals | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5853716A (en) | 1995-07-28 | 1998-12-29 | Yale University | Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| IL127211A0 (en) | 1996-05-31 | 1999-09-22 | Genetic Therapy Inc | Prevention of graft-versus-host disease with t-cells including polynucleotides encoding negative selective markers |
| WO1998008541A1 (en) | 1996-08-30 | 1998-03-05 | Genzyme Corporation | Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6406861B1 (en) | 1998-10-07 | 2002-06-18 | Cell Genesys, Inc. | Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration |
| US6464976B1 (en) | 1999-09-07 | 2002-10-15 | Canji, Inc. | Methods and compositions for reducing immune response |
| WO2003094939A1 (en) * | 2002-05-10 | 2003-11-20 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
-
2000
- 2000-08-10 US US09/636,597 patent/US6565831B1/en not_active Expired - Lifetime
-
2001
- 2001-07-17 AR ARP010103413A patent/AR029839A1/es unknown
- 2001-07-20 EP EP08006362A patent/EP2016948A3/en not_active Withdrawn
- 2001-07-20 EP EP08006359A patent/EP2027866A1/en not_active Withdrawn
- 2001-07-20 ZA ZA200300411A patent/ZA200300411B/xx unknown
- 2001-07-20 MX MX2014008295A patent/MX358055B/es unknown
- 2001-07-20 ES ES01953727T patent/ES2317921T3/es not_active Expired - Lifetime
- 2001-07-20 AU AU2001276218A patent/AU2001276218B8/en not_active Expired
- 2001-07-20 CA CA002415750A patent/CA2415750C/en not_active Expired - Lifetime
- 2001-07-20 IL IL15384601A patent/IL153846A0/xx unknown
- 2001-07-20 DE DE60137631T patent/DE60137631D1/de not_active Expired - Lifetime
- 2001-07-20 AT AT01953727T patent/ATE422358T1/de not_active IP Right Cessation
- 2001-07-20 WO PCT/CA2001/001055 patent/WO2002011742A2/en active IP Right Grant
- 2001-07-20 MX MXPA03000859A patent/MXPA03000859A/es active IP Right Grant
- 2001-07-20 EP EP01953727A patent/EP1309334B1/en not_active Expired - Lifetime
- 2001-07-20 JP JP2002517077A patent/JP2004505924A/ja active Pending
- 2001-07-20 AU AU7621801A patent/AU7621801A/xx active Pending
- 2001-07-20 NZ NZ523509A patent/NZ523509A/en unknown
- 2001-07-20 BR BR0113128-1A patent/BR0113128A/pt not_active IP Right Cessation
-
2003
- 2003-01-08 IL IL153846A patent/IL153846A/en active IP Right Grant
- 2003-03-28 US US10/401,032 patent/US7014847B2/en not_active Expired - Fee Related
-
2005
- 2005-10-21 US US11/255,849 patent/US7452723B2/en not_active Expired - Fee Related
-
2007
- 2007-05-30 US US11/809,195 patent/US7708987B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7452723B2 (en) | 2008-11-18 |
| BR0113128A (pt) | 2003-07-22 |
| US20030215443A1 (en) | 2003-11-20 |
| JP2004505924A (ja) | 2004-02-26 |
| US7014847B2 (en) | 2006-03-21 |
| AU2001276218B2 (en) | 2006-08-03 |
| EP1309334B1 (en) | 2009-02-11 |
| AU2001276218B8 (en) | 2006-08-24 |
| AU7621801A (en) | 2002-02-18 |
| IL153846A (en) | 2010-12-30 |
| EP2027866A1 (en) | 2009-02-25 |
| US20060073166A1 (en) | 2006-04-06 |
| AR029839A1 (es) | 2003-07-16 |
| EP2016948A2 (en) | 2009-01-21 |
| CA2415750A1 (en) | 2002-02-14 |
| US6565831B1 (en) | 2003-05-20 |
| WO2002011742A3 (en) | 2002-04-18 |
| ES2317921T3 (es) | 2009-05-01 |
| US7708987B2 (en) | 2010-05-04 |
| EP2016948A3 (en) | 2009-01-28 |
| WO2002011742A2 (en) | 2002-02-14 |
| EP1309334A2 (en) | 2003-05-14 |
| ATE422358T1 (de) | 2009-02-15 |
| US20080075729A1 (en) | 2008-03-27 |
| CA2415750C (en) | 2006-03-28 |
| ZA200300411B (en) | 2004-01-26 |
| IL153846A0 (en) | 2003-07-31 |
| DE60137631D1 (de) | 2009-03-26 |
| NZ523509A (en) | 2004-11-26 |
| MXPA03000859A (es) | 2004-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358055B (es) | Metodos para evitar el reconocimiento de reovirus para el tratamiento de trastornos proliferantes celulares. | |
| IL144043A (en) | Use of reovirus for the preparation of a pharmaceutical composition for the treatment of cellular proliferative disorders | |
| Brocato et al. | A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus | |
| BR112012014174A2 (pt) | Partículaterapêuta, sistema para proteger uma célula do dano oxidativo e sistema para focar magneticamente uma proteína para um dispositivo implantado | |
| NZ614571A (en) | Vaccines containing canine parvovirus genetic variants | |
| Macdonald | Immunosuppression caused by antigen feeding II. Suppressor T cells mask Peyer's patch B cell priming to orally administered antigen | |
| UA110328C2 (en) | Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration | |
| DK1420804T3 (da) | Fremgangsmåder og sammensætninger til bekæmpelse af coccidiose | |
| Villegas-Mendez et al. | Gamma interferon mediates experimental cerebral malaria by signaling within both the hematopoietic and nonhematopoietic compartments | |
| PH12021550778A1 (en) | Genetically modified sterile avians and method for the reconstitution thereof | |
| McDonald et al. | Regenerative arrest of inflamed peripheral nerves: role of nitric oxide | |
| Playford et al. | Effect of an immunomodulatory feed additive on markers of immunity in pasture‐fed dairy cows | |
| Bagu et al. | The effect of parity of the dam on sexual maturation, serum concentrations of metabolic hormones and the response to luteinizing hormone releasing hormone in bull calves | |
| Liu et al. | Secretion of IFN-γ by transgenic mammary epithelial cells in vitro reduced mastitis infection risk in goats | |
| Varley et al. | Attempt to control parturition in the sow using an oral progestogen. | |
| Spector et al. | Immune enhancement by conditioning of senescent mice. Comparison of old and young mice in learning ability and in ability to increase natural killer cell activity and other host defense reactions in response to a conditioned stimulus. | |
| EP1043028A4 (en) | METHOD FOR PREVENTING OR TREATING MAMMITIS | |
| GB2571493A (en) | Methods and products for reducing resistance to anti-parasitic agents | |
| Dkhil et al. | Nanoparticles Against Eimeriosis | |
| Pratsch et al. | Does training reduce stress during transport in cats? | |
| Vico et al. | The addition of galacto-oligosaccharides on the feed for the control of salmonellosis in fattening pigs | |
| Soni et al. | Theileriosis in An Indigenous Bullock | |
| Nakata et al. | Bone marrow‐derived cells contribute to regeneration of injured prostate epithelium and stroma | |
| EP4295862A3 (en) | Coronavirus vaccine | |
| Dhaka | Evaluation of efficacy of Modified Co-Synch Plus Protocol with or without intravaginal progesterone device for estrus induction in Murrah buffalo |